Biogen (BIIB) Stock Analysis

June 13, 2026

Here is a fundamental analysis of Biogen (BIIB), benchmarking its profitability, financial strength, dividend and valuation against its industry group peers.

Performance

Cumulative Growth

BIIB

GSPC

Biogen (BIIB) vs. S&P 500 (GSPC): Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Biogen (BIIB) and S&P 500 (GSPC). Returns over one year are annualized.

Performance at a Glance

Biogen (BIIB) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: BIIB	Industry group median
1-Year Return	51.20%	44.56%

Risk

Drawdown

BIIB

GSPC

Biogen (BIIB) vs. S&P 500 (GSPC): Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Risk at a Glance

Biogen (BIIB) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: BIIB	Industry group median
1-Year Volatility	33.53%	67.11%
Beta	0.17	0.93

Company Profile

Company profile fields for Biogen (BIIB)
Profile Item	BIIB
Name	Biogen Inc.
Country/Region	United States
GICS Sector	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology
GICS Sub-Industry	Biotechnology
Market Capitalization	29.53 billion USD
Currency	USD
Exchange	Nasdaq
Listing Date	September 17, 1991
Security Type	Common Stock

Valuation

Price-to-Earnings Ratio (TTM)

Biogen (BIIB) trades at P/E ratio of 21.51, near the industry’s usual earnings multiple. The stock is not showing a clear peer discount or premium on trailing earnings.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.51

Group distribution

Max: 77.14
Q3: 43.78
Median: 24.68
BIIB: 21.51
Q1: 15.27
Min: 1.70

Largest peers

ABBV: 111.09
LLY: 40.32
MRK: 33.54
JNJ: 27.94
AZN: 26.96
NVS: 21.93
BIIB: 21.51

Where Biogen (BIIB) stands on P/E ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Price-to-Sales Ratio (TTM)

Biogen (BIIB) trades at 2.97 on P/S ratio, in the lower sales-valuation quartile for its industry. That points to a cheaper revenue stream than most peers, with margin quality still doing the heavy lifting.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.97

Group distribution

Max: 55.38
Q3: 24.42
Median: 6.98
Q1: 3.30
BIIB: 2.97
Min: 0.01

Largest peers

LLY: 13.98
ABBV: 6.40
JNJ: 6.02
NVS: 5.16
AZN: 4.59
MRK: 4.47
BIIB: 2.97

Where Biogen (BIIB) stands on P/S ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Price-to-Book Ratio (MRQ)

Biogen (BIIB) trades at 1.58 on P/B ratio, in the lower book-value quartile for its industry. Investors are paying less for the balance-sheet equity than they pay for most peers, with returns on that equity still central to the read.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.58

Group distribution

Max: 13.23
Q3: 6.38
Median: 3.46
Q1: 1.64
BIIB: 1.58
Min: -5.17

Largest peers

LLY: 32.45
NVS: 7.58
JNJ: 7.14
MRK: 6.41
AZN: 5.85
BIIB: 1.58
ABBV: -60.45

Where Biogen (BIIB) stands on P/B ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Valuation at a Glance

Biogen (BIIB) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: BIIB	Industry group median
Price-to-Earnings Ratio (TTM)	21.51	24.68
Price-to-Sales Ratio (TTM)	2.97	6.98
Price-to-Book Ratio (MRQ)	1.58	3.46
Free Cash Flow Yield	6.54%	-2.37%

Profitability

Return on Equity (TTM)

Biogen (BIIB) posts ROE of 7.70%, in the upper peer quartile. That suggests the company earns more from each dollar of shareholders’ equity than most industry peers, a useful capital-efficiency signal.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.70%

Group distribution

Max: 101.32%
BIIB: 7.70%
Q3: 2.92%
Median: -31.26%
Q1: -62.68%
Min: -158.89%

Largest peers

LLY: 107.46%
NVS: 34.93%
JNJ: 26.42%
AZN: 23.48%
MRK: 18.94%
BIIB: 7.70%
ABBV: --

Where Biogen (BIIB) stands on ROE within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Net Profit Margin (TTM)

Biogen (BIIB) keeps 13.81% of revenue as net profit on net margin, above the industry benchmark range. That is unusually strong bottom-line conversion, though tax effects, asset sales, or other one-off gains should be checked before treating it as durable.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.81%

Group distribution

BIIB: 13.81%
Max: 12.76%
Q3: 4.00%
Median: 0.00%
Q1: -2.26%
Min: -11.53%

Largest peers

LLY: 34.99%
NVS: 23.92%
JNJ: 21.83%
AZN: 17.19%
BIIB: 13.81%
MRK: 13.59%
ABBV: 5.79%

Where Biogen (BIIB) stands on net margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Operating Profit Margin (TTM)

Biogen (BIIB) turns 22.90% of revenue into operating profit, putting operating margin in the upper peer quartile. Before financing and taxes enter the picture, the day-to-day business keeps more of each sales dollar than most industry peers.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.90%

Group distribution

Max: 100.30%
BIIB: 22.90%
Q3: 4.40%
Median: 0.00%
Q1: -131.52%
Min: -333.43%

Largest peers

LLY: 49.39%
MRK: 38.60%
ABBV: 32.16%
NVS: 30.48%
AZN: 27.94%
JNJ: 27.41%
BIIB: 22.90%

Where Biogen (BIIB) stands on operating margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Profitability at a Glance

Biogen (BIIB) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: BIIB	Industry group median
Return on Equity (TTM)	7.70%	-31.26%
Return on Assets (TTM)	5.95%	-14.70%
Net Profit Margin (TTM)	13.81%	0.00%
Operating Profit Margin (TTM)	22.90%	0.00%
Gross Profit Margin (TTM)	78.72%	33.58%

Financial Strength

Current Ratio (MRQ)

Biogen (BIIB) has current ratio of 3.07, in the healthier middle range for its industry. The short-term asset cushion looks balanced relative to peers rather than stretched thin.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.07

Group distribution

Max: 24.81
Q3: 11.75
Median: 5.57
BIIB: 3.07
Q1: 2.69
Min: 0.23

Largest peers

BIIB: 3.07
LLY: 1.50
MRK: 1.30
JNJ: 1.03
AZN: 0.91
NVS: 0.85
ABBV: 0.80

Where Biogen (BIIB) stands on current ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Debt-to-Equity Ratio (MRQ)

Biogen (BIIB) has debt-to-equity ratio of 0.35, roughly in line with the peer group’s normal leverage range. Its mix of debt and equity looks typical for the industry.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.35

Group distribution

Max: 1.60
Q3: 0.68
BIIB: 0.35
Median: 0.15
Q1: 0.02
Min: 0.00

Largest peers

LLY: 1.39
NVS: 1.21
MRK: 1.07
AZN: 0.72
JNJ: 0.68
BIIB: 0.35
ABBV: --

Where Biogen (BIIB) stands on debt-to-equity ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Financial Strength at a Glance

Biogen (BIIB) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: BIIB	Industry group median
Current Ratio (MRQ)	3.07	5.57
Debt-to-Equity Ratio (MRQ)	0.35	0.15
Net Debt / EBITDA	0.64	1.09

Dividends

Dividend Yield (TTM)

Biogen (BIIB) pays no dividend, leaving dividend yield at 0.00% this period. Shareholders may still receive value through reinvestment or buybacks, but there is no dividend income to compare here.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution

BIIB: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Largest peers

NVS: 3.10%
ABBV: 3.04%
MRK: 2.86%
JNJ: 2.23%
AZN: 1.77%
LLY: 0.61%
BIIB: 0.00%

Where Biogen (BIIB) stands on dividend yield within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Payout Ratio (TTM)

Biogen (BIIB) paid no earnings out as dividends this period, leaving payout ratio at 0.00%. There is no dividend payout to size against earnings.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution

BIIB: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Largest peers

ABBV: 325.98%
MRK: 93.52%
NVS: 67.91%
JNJ: 60.25%
AZN: 47.70%
LLY: 22.13%
BIIB: 0.00%

Where Biogen (BIIB) stands on payout ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividends at a Glance

Biogen (BIIB) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: BIIB	Industry group median
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%